Moderna, INC Form 4 insider transactions

Moderna's Chief Financial Officer, James M. Mock, reported the acquisition of common stock through restricted stock unit conversions and subsequent sales to cover tax obligations on May 27 and May 28, 2025.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported the acquisition of common stock through the vesting of restricted stock units and the subsequent disposition of shares to cover tax obligations.

Moderna President Stephen Hoge reported the acquisition of common stock through restricted stock unit vesting and subsequent sales to cover tax obligations.

Director Elizabeth E. Tallett reports the acquisition of stock options and restricted stock units in Moderna, Inc.

Director Paul Sagan acquired 25,512 stock options in Moderna, Inc. on April 30, 2025, according to a Form 4 filing.

Director David M. Rubenstein reports acquisition and disposal of Moderna common stock and derivative securities.

Director Francois Nader reports acquisition of stock options and restricted stock units in Moderna, Inc.

Director Elizabeth G. Nabel reports acquisition and disposal of Moderna (MRNA) common stock and restricted stock units.

Director Abbas Hussain reports the vesting and conversion of restricted stock units into Moderna common stock.

Director Sandra Horning reports acquisition and disposal of Moderna (MRNA) stock and restricted stock units on April 30, 2025.

Director Noubar Afeyan acquired stock options for 25,512 shares of Moderna, Inc. on April 30, 2025.

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of company stock and restricted stock units on April 4, 2025.

Chief Legal Officer of Moderna, Shannon Thyme Klinger, reports the acquisition and disposal of common stock and restricted stock units.

Moderna's CEO, Stephane Bancel, indirectly acquired 160,314 shares of Moderna's common stock through Boston Biotech Ventures, LLC and OCHA LLC, entities in which he holds a majority equity interest.

Director Paul Sagan reports purchasing Moderna shares and changes in beneficial ownership, including transfers to family trusts.

James Mock, Moderna's Chief Financial Officer, reported the acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the vesting of restricted stock units and subsequent tax withholding, along with the grant of new stock options and restricted stock units.

Stephen Hoge, President of Moderna, reports the acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options.

Moderna's CEO, Stephane Bancel, reported the acquisition of stock options and changes in beneficial ownership of Moderna shares.

Moderna's President, Stephen Hoge, reports the acquisition and disposal of company stock and derivative securities, including transactions related to restricted stock units.

James Mock, Moderna's Chief Financial Officer, reported the vesting and conversion of performance and restricted stock units into common stock, along with the withholding of shares to cover tax obligations.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reports the vesting and conversion of restricted stock units into common stock, along with related tax withholding transactions.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reports the vesting of performance-based restricted stock units and subsequent tax withholding.

Moderna's President, Stephen Hoge, reports the vesting of performance-based restricted stock units and subsequent tax withholding.

Moderna's CEO, Stephane Bancel, reported the vesting of performance-based restricted stock units and the subsequent withholding of shares to cover tax obligations.

Stephen Hoge, President of Moderna, reports the vesting of restricted stock units and subsequent tax withholding, resulting in changes to his beneficial ownership of company stock.

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of company stock and restricted stock units on January 3, 2025.

Moderna's Chief Legal Officer, Shannon Klinger, acquired and disposed of company stock, including shares to cover tax obligations related to vesting restricted stock units.

Moderna's Chief Financial Officer, James Mock, was granted 188,761 restricted stock units that vest over time.

Moderna's Chief Legal Officer, Shannon Klinger, received 188,761 restricted stock units that will vest over time.